Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case
{{output}}
the epidermal growth-factor receptor (EGFR) and its signaling pathway have become a major target for therapy of non-small cell lung cancer (NSCLC). After the BR.21 study showed its effectiveness and its tolerability in older patients, erlotinib, a specific EGF... ...
